BSX Form 144: Insider to sell 50,000 shares via Morgan Stanley on 10/01/2025

Rhea-AI Filing Summary

Insider sale notice for Boston Scientific (BSX): This Form 144 reports a proposed sale of 50,000 shares of common stock through Morgan Stanley Smith Barney LLC on 10/01/2025 with an aggregate market value of $4,923,325 and 1,481,751,634 shares outstanding. The securities were acquired and are to be sold following a stock option exercise on 10/01/2025 with cash payment. The filer (identified in past sales as Joseph M. Fitzgerald) previously sold 50,000 shares on 09/02/2025 for $5,271,415 and 50,000 shares on 08/01/2025 for $5,231,665. The filer certifies no undisclosed material information and includes standard Rule 144 representations.

Positive

• Form 144 filed and discloses planned 50,000-share sale on 10/01/2025 through Morgan Stanley
• Source of shares clearly stated as a stock option exercise on 10/01/2025 with cash payment
• Prior sales on 09/02/2025 and 08/01/2025 are disclosed with gross proceeds, supporting transparency

Negative

• None.

Insights

Financial Analyst

TL;DR Insider filing shows routine disposition after option exercise; disclosed prior monthly sales are small relative to total shares outstanding.

The Form 144 documents a proposed 50,000-share sale executed through Morgan Stanley on 10/01/2025 following a stock option exercise the same day. The filing also records two recent sales of 50,000 shares each on 09/02/2025 and 08/01/2025 with gross proceeds reported. Taken together, these transactions total 150,000 shares disclosed over the three-month period. The filing meets disclosure requirements and provides clear transaction dates, source of shares, and gross proceeds, enabling investors to track insider liquidity without raising immediate material financial concerns based on the disclosed sizes.

Corporate Governance Expert

TL;DR The filing is a routine compliance disclosure of insider sales following option exercise; documentation appears complete for Rule 144 purposes.

The filer identifies the nature of acquisition as a stock option exercise and certifies the absence of undisclosed material information. The use of a broker and exact sale date are provided, and prior sales within the past three months are listed with gross proceeds, which supports transparency. There is no indication in this filing of any unusual trading pattern or governance issue beyond standard insider liquidity activity.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	50000	4923325.00	1481751634	10/01/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2025	Stock Option Exercise	ISSUER			50000	10/01/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JOSEPH M FITZGERALD 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234	Common	09/02/2025	50000	5271415.00
JOSEPH M FITZGERALD 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234	Common	08/01/2025	50000	5231665.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Boston Scientific (BSX) disclose?

The Form 144 discloses a proposed sale of 50,000 common shares to be sold on 10/01/2025 through Morgan Stanley, acquired via a stock option exercise on the same date.

Who previously sold Boston Scientific shares for the account in this filing?

The filing lists prior sales by Joseph M. Fitzgerald of 50,000 shares on 09/02/2025 for $5,271,415 and 50,000 shares on 08/01/2025 for $5,231,665.

What is the aggregate market value and shares outstanding reported?

The aggregate market value reported for the proposed 50,000-share sale is $4,923,325.00 and the number of shares outstanding is 1,481,751,634.

What was the nature of consideration for the acquired securities?

The securities were acquired via a stock option exercise on 10/01/2025 and the payment type is listed as Cash.

Does the filer make any representations about material nonpublic information?

Yes, the filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.

Which broker is named for the proposed sale?

The broker named for the proposed sale is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.